North American Scientific
This article was originally published in The Gray Sheet
Executive Summary
Firm completes stock-swap acquisition of radiopharmaceutical developer Theseus Oct. 16. The price tag of roughly $18.5 mil. includes about $10.5 mil. of Theseus' debt. Ongoing European and U.S. clinical trials for Theseus' Apomate imaging agent are being funded by NAS (1"The Gray Sheet" Nov. 30, 1998, p. 23)